Uzm. Dr. Özde Melisa Celayir

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

Cancers, 2026

DOI 10.3390/cancers18121979 PMID 42352512 Frei zugänglicher VolltextQuelle: OpenAlex

Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

Medicina, 2026

DOI 10.3390/medicina62112136 Frei zugänglicher VolltextQuelle: OpenAlex

Real-World Outcomes of Fosaprepitant-Containing Prophylaxis in Patients Receiving Highly and Moderately Emetogenic Chemotherapy: A Two-Center Retrospective Study

SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, 2026

DOI 10.14744/semb.2026.32391 PMID 42824916 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

Diagnostics, 2026

DOI 10.3390/diagnostics16182890 PMID 42793675 Frei zugänglicher VolltextQuelle: ORCID

Prognostic Value of the Lung Immune Prognostic Index in Advanced Non–Small Cell Lung Cancer Receiving Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

2026

DOI 10.20944/preprints202605.1554.v1 Frei zugänglicher VolltextQuelle: ORCID

Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study

Journal of Neuro-Oncology, 2026

DOI 10.1007/s11060-025-05415-0 PMID 41492105 Quelle: OpenAlex

BIOMARKERS AND PERSONALIZED MEDICINE IN OLDER CANCER PATIENTS

Turkiye Klinikleri eBooks, 2026

DOI 10.5336/978-625-91269-7-5_p117 Quelle: OpenAlex

Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.e20659 Quelle: OpenAlex

The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey

Cancers, 2025

DOI 10.3390/cancers17091592 PMID 40361516 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

The Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Multicenter Real-World Study from Turkey

2025

DOI 10.20944/preprints202504.0284.v1 Frei zugänglicher VolltextQuelle: ORCID

The Relationship Between GRIm Score and Prognosis in Patients with Metastatic Pancreatic Cancer

DergiPark (Istanbul University), 2025

Quelle: OpenAlex

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

International Journal of Clinical Oncology, 2024

DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 Zitationen (Europe PMC) Quelle: OpenAlex

71P The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: A Turkish Oncology Group (TOG) study

ESMO Open, 2024

DOI 10.1016/j.esmoop.2024.102300 Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Journal of Chemotherapy, 2024

DOI 10.1080/1120009x.2024.2330835 PMID 38497444 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

BMC Cancer, 2023

DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

Acibadem Universitesi Saglik Bilimleri Dergisi, 2023

DOI 10.31067/acusaglik.1247538 Frei zugänglicher VolltextQuelle: OpenAlex

Systemic treatment of soft tissue sarcoma

TOTBİD Dergisi, 2023

DOI 10.5578/totbid.dergisi.2023.74 Frei zugänglicher VolltextQuelle: ORCID

Is virtual nutritional counseling efficacious for cancer patients during the COVID-19 pandemic?

Journal of Telemedicine and Telecare, 2023

DOI 10.1177/1357633x231158831 PMID 36912038 6 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

230P Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

ESMO Open, 2023

DOI 10.1016/j.esmoop.2023.101418 Frei zugänglicher VolltextQuelle: OpenAlex

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Breast, 2022

DOI 10.1016/j.breast.2022.09.009 PMID 36208540 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Association between high initial CEA, CA 19-9 levels and HER-2 status and their prognostic values on overall survival in metastatic gastric cancer.

2021

Quelle: ORCID

Evaluation of HER2 overexpression, clinicopathological characteristics, and factors affecting survival in gastric cancer

The Medical Bulletin of Sisli Hospital, 2021

DOI 10.14744/semb.2021.23356 PMID 34349600 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

The Effects of Initial Symptoms on the Prognosis in Patients with Stomach Cancer

Medical Bulletin of Haseki, 2015

Quelle: ORCID

A RARE PRESENTATION: UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF COLON

ASIAN ACADEMIC RESEARCH JOURNAL OF MULTIDISCIPLINARY, 2015

Quelle: ORCID